Notice2024-25580
Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production Activity; Merck, Sharp & Dohme LLC; (Pharmaceutical Products for Research and Development); Rahway, New Jersey
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 4, 2024
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 213 (Monday, November 4, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 213 (Monday, November 4, 2024)]
[Notices]
[Pages 87542-87543]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-25580]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-56-2024]
Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production
Activity; Merck, Sharp & Dohme LLC; (Pharmaceutical Products for
Research and Development); Rahway, New Jersey
Merck, Sharp & Dohme LLC submitted a notification of proposed
production activity to the FTZ Board (the Board) for its facility in
Rahway, New Jersey, within Subzone 49Y. The notification conforming to
the requirements of the Board's regulations (15 CFR 400.22) was
received on October 18, 2024.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished
product(s) and material(s)/component(s) would be added to the
production authority that the Board previously approved for the
operation, as reflected on the Board's website.
The proposed finished products for research and development include
MK-2828 and MK-3214 cardiovascular disease drug products, MK-2420
autoimmune disease drug product, MK-4646 HIV drug product, and MK-0472
oncology drug product (duty free).
The proposed foreign-status materials/components include MK-2828
and MK-3214 cardiovascular disease active pharmaceutical ingredients
(API), MK-2420 autoimmune disease API, MK-4646 HIV API, and MK-0472
oncology API (duty rate, 6.5%). The request indicates that certain
materials/components are subject to duties under section 301 of the
Trade Act of 1974 (section 301), depending on the country of origin.
The applicable section 301 decisions require subject merchandise to be
admitted to FTZs in privileged foreign status (19 CFR 146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#4422303e0430362520216a232b32"><span class="__cf_email__" data-cfemail="f99f8d83b98d8b989d9cd79e968f">[email protected]</span></a>. The closing period for their receipt is December 16,
2024.
[[Page 87543]]
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Diane Finver at
<a href="/cdn-cgi/l/email-protection#13577a727d763d557a7d6576615367617277763d747c65"><span class="__cf_email__" data-cfemail="83c7eae2ede6adc5eaedf5e6f1c3f7f1e2e7e6ade4ecf5">[email protected]</span></a>.
Dated: October 30, 2024.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2024-25580 Filed 11-1-24; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on November 4, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.